semaglutide nda Last week's expiry of the patent for semaglutide—the active ingredient in Novo Nordisk's blockbuster drugs that are used to treat both diabetes and obesity—unleashed a flurry of launches of low-cost generic versions Rybelsus (Semaglutide) for the Treatment

In clinical trials for weight management, tirzepatide produced average weight loss of 20-25% of body weight, roughly double what semaglutide achieves at comparable endpoints

Community featuressuch as achievement badges, opt-in leaderboards, and shareable session summariesadd a sense of progression without pushing players beyond comfortable limits

Some may begin noticing initial changes in appetite and eating patterns within the first few weeks of consistent use, while more noticeable changes in body weight and metabolic health may emerge over 36 months

They are often combined in supplements to improve skin tone, reduce hyperpigmentation, and promote overall health

AI-enabled drug discovery could revolutionize R&D A rising cadence of large pharmaAI platform collaborations (e.g., Lilly Nimbus for AI-driven oral metabolic candidates